Stephane Helleringer1, Andrew Noymer2. 1. Department of population, family and reproductive health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. 2. Population Health and Disease Prevention, Program in Public Health, University of California, Irvine, California, USA.
Abstract
BACKGROUND: An EVD outbreak may reduce life expectancy directly (due to high mortality among EVD cases) and indirectly (e.g., due to lower utilization of healthcare and subsequent increases in non-EVD mortality). In this paper, we investigated the direct effects of EVD on life expectancy in Liberia, Sierra Leone and Guinea (LSLG thereafter). METHODS: We used data on EVD cases and deaths published in situation reports by the World Health Organization (WHO), as well as data on the age of EVD cases reported from patient datasets. We used data on non-EVD mortality from the most recent life tables published prior to the EVD outbreak. We then formulated three scenarios based on hypotheses about a) the extent of under-reporting of EVD cases and b) the EVD case fatality ratio. For each scenario, we re-estimated the number of EVD deaths in LSLG and we applied standard life table techniques to calculate life expectancy. RESULTS: In Liberia, possible reductions in life expectancy resulting from EVD deaths ranged from 1.63 year (low EVD scenario) to 5.56 years (high EVD scenario), whereas in Sierra Leone, possible life expectancy declines ranged from 1.38 to 5.10 years. In Guinea, the direct effects of EVD on life expectancy were more limited (<1.20 year). CONCLUSIONS: Our high EVD scenario suggests that, due to EVD deaths, life expectancy may have declined in Liberia and Sierra Leone to levels these two countries had not experienced since 2001-2003, i.e., approximately the end of their civil wars. The total effects of EVD on life expectancy may however be larger due to possible concomitant increases in non-EVD mortality during the outbreak.
BACKGROUND: An EVD outbreak may reduce life expectancy directly (due to high mortality among EVD cases) and indirectly (e.g., due to lower utilization of healthcare and subsequent increases in non-EVD mortality). In this paper, we investigated the direct effects of EVD on life expectancy in Liberia, Sierra Leone and Guinea (LSLG thereafter). METHODS: We used data on EVD cases and deaths published in situation reports by the World Health Organization (WHO), as well as data on the age of EVD cases reported from patient datasets. We used data on non-EVD mortality from the most recent life tables published prior to the EVD outbreak. We then formulated three scenarios based on hypotheses about a) the extent of under-reporting of EVD cases and b) the EVD case fatality ratio. For each scenario, we re-estimated the number of EVD deaths in LSLG and we applied standard life table techniques to calculate life expectancy. RESULTS: In Liberia, possible reductions in life expectancy resulting from EVD deaths ranged from 1.63 year (low EVD scenario) to 5.56 years (high EVD scenario), whereas in Sierra Leone, possible life expectancy declines ranged from 1.38 to 5.10 years. In Guinea, the direct effects of EVD on life expectancy were more limited (<1.20 year). CONCLUSIONS: Our high EVD scenario suggests that, due to EVD deaths, life expectancy may have declined in Liberia and Sierra Leone to levels these two countries had not experienced since 2001-2003, i.e., approximately the end of their civil wars. The total effects of EVD on life expectancy may however be larger due to possible concomitant increases in non-EVD mortality during the outbreak.
Entities:
Keywords:
Demography; EBOV; Guinea; Liberia; Sierra Leone; ebola; life expectancy
Authors: Rashid Ansumana; Kathryn H Jacobsen; Foday Sahr; M'baimba Idris; Henry Bangura; Mohamed Boie-Jalloh; Joseph M Lamin; Santigie Sesay Journal: N Engl J Med Date: 2014-12-24 Impact factor: 91.245
Authors: Martin I Meltzer; Charisma Y Atkins; Scott Santibanez; Barbara Knust; Brett W Petersen; Elizabeth D Ervin; Stuart T Nichol; Inger K Damon; Michael L Washington Journal: MMWR Suppl Date: 2014-09-26
Authors: Richard A White; Emily MacDonald; Birgitte Freiesleben de Blasio; Karin Nygård; Line Vold; John-Arne Røttingen Journal: PLoS Curr Date: 2015-01-30
Authors: C Poletto; M F Gomes; A Pastore y Piontti; L Rossi; L Bioglio; D L Chao; I M Longini; M E Halloran; V Colizza; A Vespignani Journal: Euro Surveill Date: 2014-10-23
Authors: Junerlyn Agua-Agum; Archchun Ariyarajah; Bruce Aylward; Isobel M Blake; Richard Brennan; Anne Cori; Christl A Donnelly; Ilaria Dorigatti; Christopher Dye; Tim Eckmanns; Neil M Ferguson; Pierre Formenty; Christophe Fraser; Erika Garcia; Tini Garske; Wes Hinsley; David Holmes; Stéphane Hugonnet; Swathi Iyengar; Thibaut Jombart; Ravi Krishnan; Sascha Meijers; Harriet L Mills; Yasmine Mohamed; Gemma Nedjati-Gilani; Emily Newton; Pierre Nouvellet; Louise Pelletier; Devin Perkins; Steven Riley; Maria Sagrado; Johannes Schnitzler; Dirk Schumacher; Anita Shah; Maria D Van Kerkhove; Olivia Varsaneux; Niluka Wijekoon Kannangarage Journal: N Engl J Med Date: 2014-12-24 Impact factor: 91.245
Authors: John Ly; Vidiya Sathananthan; Thomas Griffiths; Zahir Kanjee; Avi Kenny; Nicholas Gordon; Gaurab Basu; Dale Battistoli; Lorenzo Dorr; Breeanna Lorenzen; Dana R Thomson; Ami Waters; Uriah G Moore; Ruth Roberts; Wilmot L Smith; Mark J Siedner; John D Kraemer Journal: PLoS Med Date: 2016-08-02 Impact factor: 11.069
Authors: Bradley H Wagenaar; Orvalho Augusto; Jason Beste; Stephen J Toomay; Eugene Wickett; Nelson Dunbar; Luke Bawo; Chea Sanford Wesseh Journal: PLoS Med Date: 2018-02-20 Impact factor: 11.069
Authors: E Bonnet; O Bodson; F Le Marcis; A Faye; N E Sambieni; F Fournet; F Boyer; A Coulibaly; K Kadio; F B Diongue; V Ridde Journal: BMC Public Health Date: 2021-08-02 Impact factor: 3.295